Patent · US Active

Method for the treament of multiple myeloma or non-hodgkins lymphoma with anti-CD38 antibody in combination with thalidomine, lenalidomids, or pomalidomide

US10308722B2 · kind B2 · utility

0Cited by

6References

20Claims

0Family size

Assignee

MORPHOSYS AG · DE

Inventors

Lisa Rojkjaer · Hedingen, CH
Rainer Boxhammer · Aying, DE
Jan Endell · Munich, DE
Mark Winderlich · Munich, DE
Christofer Samuelsson · Holzkirchen, DE

Key dates

Filing date	Aug 7, 2017
Grant date	Jun 4, 2019
Priority date	—
Expiry date	Aug 12, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure is directed to a method of treating multiple myeloma or non-hodgkins lymphoma with a pharmaceutical composition comprising an anti-CD38 antibody in combination with thalidomide, lenalidomide, or pomalidomide.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.